

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/654,499	09/01/2000	Michelle A.J. Palmer	4085-226-27	7006
7:	590 09/25/2002			
Steven B Kelber Piper Marbury Rudnick & Wolfe LLP 1200 Nineteenth Street N W			EXAMINER	
			ULM, JOHN D	
Washington, DC 20036-2412				
			ART UNIT	PAPER NUMBER
			1646	<u> </u>
			DATE MAILED: 09/25/2002	13

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/654,499

Applicant(s)

Palmer et al.

Examiner

John Ulm

Art Unit **1646**



	•	on the cover sheet with the correspondence address		
	or Reply			
	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.	TO EXPIRE 3 MONTH(S) FROM		
		no event, however, may a reply be timely filed after SIX (6) MONTHS from the		
-	date of this communication. eriod for reply specified above is less than thirty (30) days, a reply within t	he statutory minimum of thirty (30) days will be considered timely.		
	eriod for reply is specified above, the maximum statutory period will apply to reply within the set or extended period for reply will, by statute, cause t	and will expire SIX (6) MONTHS from the mailing date of this communication.		
- Any re	bly received by the Office later than three months after the mailing date of patent term adjustment. See 37 CFR 1.704(b).			
Status	patent term adjustment. See 37 CFN 1.704(b).			
1) 💢	Responsive to communication(s) filed on Jul 22, 2			
2a) 💢	This action is FINAL . 2b) ☐ This ac	tion is non-final.		
3) 🗆	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.			
Disposit	ion of Claims			
4) 💢	Claim(s) <u>1-37</u>	is/are pending in the application.		
4	a) Of the above, claim(s) <u>19 and 27-30</u>	is/are withdrawn from consideration.		
5) 🗆	Claim(s)	is/are allowed.		
6) 💢	Claim(s) 1-18, 20-26, and 31-37	is/are rejected.		
7) 🗆	Claim(s)	is/are objected to.		
8) 🗌	Claims	are subject to restriction and/or election requirement.		
Applica	tion Papers			
9) 🗆	The specification is objected to by the Examiner.			
10)	The drawing(s) filed on is/are	e a) \square accepted or b) \square objected to by the Examiner.		
	Applicant may not request that any objection to the	drawing(s) be held in abeyance. See 37 CFR 1.85(a).		
11)	The proposed drawing correction filed on	is: a) \square approved b) \square disapproved by the Examiner.		
	If approved, corrected drawings are required in reply	to this Office action.		
12) The oath or declaration is objected to by the Examiner.				
Priority	under 35 U.S.C. §§ 119 and 120			
13) 🗌	Acknowledgement is made of a claim for foreign p	riority under 35 U.S.C. § 119(a)-(d) or (f).		
a) 🗆	All b)□ Some* c)□ None of:			
1. Certified copies of the priority documents have been received.				
,	2. \square Certified copies of the priority documents hav	ve been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).				
*S	ee the attached detailed Office action for a list-of-th	e-certified-copies-not-received.		
14) 🗆	Acknowledgement is made of a claim for domestic			
a) The translation of the foreign language provisional application has been received.				
15)∟	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. §§ 120 and/or 121.		
Attachm		41 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s). 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) Notice of Informal Patent Application (PTO-152)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) Notice of Informal Patent Application (PTO-152) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s). 10 Other:				
A manufacture processes of a factor field to 1440/ raper riols/ · · · · · · · · · · · · · · · · · ·				

Application/Control Number: 09/654,499 Page 2

Art Unit: 1646

1) Claims 1 to 37 are pending in the instant application. Claims 14, 19, 20 and 27 have been amended and claims 31 to 37 have been added as requested by Applicant in Paper Number 12, filed 22 July of 2002.

- 2) Any objection or rejection of record which is not expressly repeated in this action has been overcome by Applicant's response and withdrawn.
- 3) The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
- The proposed drawing correction and/or the proposed substitute sheets of drawings, filed on 22 July 2002 have been approved with respect to compliance with 37 C.F.R. § 1.84(U)(1). However, the drawings in the instant application do not comply with 37 C.F.R. § 1.821(d), which requires a reference to a particular sequence identifier (SEQ ID NO:) be made in the specification and claims wherever a reference is made to that sequence. M.P.E.P. 2422.02 expressly states that "when a sequence is presented in a drawing, regardless of the format or the manner of presentation of that sequence in the drawing, the sequence must still be included in the Sequence Listing and the sequence identifier ("SEQ ID NO:X") must be used, either in the drawing or in the Brief Description of the Drawings". A proper drawing correction or corrected drawings are required in reply to the Office action to avoid abandonment of the application. The correction to the drawings will not be held in abeyance.
- 5) Claims 19 and 27 to 30, as amended, are directed to an invention that is independent or distinct from the invention originally claimed for the following reasons:

Art Unit: 1646

The assay of the originally presented invention and the assay of claims 19 and 27 to 30 are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are not disclosed as capable of use together and they have different modes of operation.

Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claims 19 and 27 to 30 are withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03.

6) Claims 1 to 18, 20 to 26 and 28 to 37 are rejected under 35 U.S.C. 103(a) as being unpatentable over the Blau et al. patent (6,342,345 B1) in view of the Barak et al. patent (5,891,646) for those reasons of record as applied to claims 1 to 18 and 24 to 30 in section 7 of Paper Number 9.

Applicant has traversed this rejection on the premise that there was no motivation to combine these two references to arrive at the claimed invention. This premise is without foundation. The examiner recognizes that obviousness can only be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art. See *In re Fine*, 837 F.2d 1071, 5 USPQ2d 1596 (Fed. Cir. 1988) and *In re Jones*, 958 F.2d 347, 21 USPQ2d 1941 (Fed. Cir.

Art Unit: 1646

1992). In this case, the Barak et al. patent expressly and specifically disclosed the desirability of detecting the interaction of a G protein with arrestin in an intact cell as a means of identifying compounds which can act as either agonist or antagonists of that receptor. The Blau et al. patent explicitly described a system for the detection of the molecular interaction between two proteins in an intact cell by expressing each of those proteins as a fusion protein comprising one member of a pair of complementary β-galactosidase mutants and expressly identified cell surface receptors as usable in the disclosed method. Given that both of these references teach methods for the detection of a specific protein-protein interaction in a living cell there was ample motivation to combine them.

In response to applicant's argument that the examiner's conclusion of obviousness is based upon improper hindsight reasoning, it must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made, and does not include knowledge gleaned only from the applicant's disclosure, such a reconstruction is proper. See *In re McLaughlin*, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971).

Applicant's argument that an artisan did not have a reasonable expectation that the interaction of a G protein-coupled receptor and an arrestin could be monitored by employing the complementation system of Blau et al. is without merit. Blau et al. is an issued U.S. patent. As such, it has a presumption of validity. The claims of Blau et al. encompass the claimed subject

Application/Control Number: 09/654,499 Page 5

Art Unit: 1646

matter of the instant application in its entirety. Several of the claims in the Blau et al. patent expressly identify "members of a signal transduction cascade" and "cell surface receptors" as proteins with which the disclosed method can be practiced. To accept Applicant's argument that an artisan did not have a reasonable expectation that the interaction of a G protein-coupled receptor and an arrestin could be monitored by employing the complementation system of Blau et al. would require one to presume that the claims of Blau et al. are invalid under 35 U.S.C. § 112, first paragraph, and such a presumption, in the absence of clear and convincing evidence of inoperability, is prohibited by 35 U.S.C. § 282.

Applicant appears to be traversing the instant rejection on the basis that neither reference disclosed the claimed invention. Such arguments are clearly unpersuasive because the instant rejection is not based upon anticipation, it is based upon obviousness, which does not require that the prior art expressly disclose the claimed invention. The instant rejection is based upon the fact that all of the elements of the claimed invention are found in these two references in conjunction with ample motivation to combine them in the manner claimed.

- 7) Applicant's arguments filed 22 July of 2002 have been fully considered but they are not persuasive for those reasons given above.
- 8) THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO

Art Unit: 1646

MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to John D. Ulm whose telephone number is (703) 308-4008. The examiner can normally be reached on Monday through Friday from 9:00 AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached at (703) 308-6564.

Official papers filed by fax should be directed to (703) 308-4242 or (703) 872-9306. Official responses under 37 C.F.R. § 1.116 should be directed to (703) 872-9307.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

JOHN ULM PRIMARY EXAMINER GROUP 1800